目次

Table of Content

1. Emergence Of CD5 Targeting Therapies
1.1 Overview
1.2 History and Development

2. CD5 As Therapeutic Target
2.1 Expression and Immune Functions
2.2 Rationale For Targeting CD5 In Therapy
2.3 CD5 As Prognostic Biomarker

3. Therapeutic Indications Involving CD5
3.1 Cancer
3.2 Autoimmune and Inflammatory Diseases
3.3 Transplantation and Graft Rejection

4. CD5 Targeting Drug Modalities and Mechanisms Of Action
4.1 Cell Therapies
4.2 Monoclonal Antibodies
4.3 Bispecific Antibodies
4.4 Drug Conjugates

5. CD5 Targeting Therapies Development Platform Technologies By Indication and Company

6. Global CD5 Targeting Therapies Clinical Trials Overview
6.1 By Company
6.2 By Country
6.3 By Indication
6.4 By Patient Segment
6.5 By Phase
6.6 By Orphan Drug Designation

7. Global CD5 Targeting Therapies Clinical Trials Insight By Company, Country, Indication and Phase
7.1 Preclinical
7.2 Phase -
7.3 Phase - I
7.4 Phase - II

8. Global CD5 Targeting Therapy Market Outlook
8.1 Current Market Developments Trends
8.2 Future Commercialization Opportunities

9. Global CD5 Targeting Therapies Market Dynamics
9.1 Favorable Development Parameters
9.2 Development Restraints To Be Resolved

10. Competitive Landscape
10.1 Artiva Biotherapeutics
10.2 Curocell
10.3 Essen Biotech
10.4 GC Cell
10.5 iCell Gene Therapeutics
10.6 March Biosciences
10.7 Precision Biotech
10.8 Vittoria Biotherapeutics

List of Figures & Tables
Figure 1-1: CD5 As Immune Modulator In Cancer and Autoimmunity
Figure 1-2: Key Milestones In CD5 Research
Figure 2-1: Suggested Ligands For CD5
Figure 2-2: CD5 - Rationale For Targeting
Figure 2-3: Prognostic Potential Of CD5
Figure 3-1: CD5 Function In Cancer
Figure 3-2: MB-105-201 Phase 2 (NCT06534060) Study - Initiation and Completion Year
Figure 3-3: MAGENTA Phase 1 (NCT03081910) Study - Initiation and Completion Year
Figure 3-4: GCC2005A-P101 Phase 1 (NCT06699771) Study - Initiation and Completion Year
Figure 3-5: VIPER 101 Phase 1 (NCT06420089) Study - Initiation and Completion Year
Figure 3-6: CD5 Function In Autoimmune and Inflammatory Diseases
Figure 3-7: CD5 - Role In Disease Pathogenesis
Figure 3-8: CD5 - Dual Role In Transplantation
Figure 3-9: CD5 In Immune Modulation Post Transplant
Figure 4-1: CD5 Targeting Drug Modalities
Figure 4-2: CD5 Targeting Cell Therapy Strategies
Figure 4-3: Xencor - CD5 x TGFandbeta;R2 Bispecific Antibody
Figure 4-4: Evolution Of Drug Conjugates Targeting CD5
Figure 5-1: SENZA5 Platform - Key Features
Figure 5-2: Vittoria Biotherapeutics - SENZA5 Platform
Figure 5-3: Vittoria Biotherapeutics - Proprietary Manufacturing Process
Figure 5-4: cCAR Technology - Advantages
Figure 5-5: ATAKandtrade; Platform - Key Characteristics
Figure 5-6: XmAb Platform - Key Focus
Figure 6-1: CD5 Targeting Therapies In Clinical Trials By Company (Number Of Therapies), 2025
Figure 6-2: CD5 Targeting Therapies In Clinical Trials By Country Number Of Therapies), 2025
Figure 6-3: CD5 Targeting Therapies In Clinical Trials By Indication Number Of Therapies), 2025
Figure 6-4: CD5 Targeting Therapies In Clinical Trials By Patient Segment Number Of Therapies), 2025
Figure 6-5: CD5 Targeting Therapies In Clinical Trials By Phase Number Of Therapies), 2025
Figure 6 6: CD5 Targeting Therapies In Clinical Trials By Orphan Drug Designation Number Of Therapies), 2025
Figure 8-1: Global CD5 Targeting Therapy Market - Future Opportunities
Figure 9-1: Global CD5 Targeting Therapy Market Favorable Development Parameters
Figure 9-2: Global CD5 Targeting Therapy Market - Challenges and Restraints
Table 2-1: CD5 In Immune Regulation
Table 3-1: CD5 Expression Pattern By Cancer